Session

IBD (Posters)

INFLAMMATORY BOWEL DISEASE AND SOLID ORGAN TRANSPLANTATION: A SINGLE CENTRE EXPERIENCE
INFLAMMATORY BOWEL DISEASE AND SOLID ORGAN TRANSPLANTATION: A SINGLE CENTRE EXPERIENCE

THE BI-DIRECTIONAL RISK OF INFLAMMATORY BOWEL DISEASE AND ANXIETY OR DEPRESSION: A SYSTEMATIC REVIEW AND META-ANALYSIS
THE BI-DIRECTIONAL RISK OF INFLAMMATORY BOWEL DISEASE AND ANXIETY OR DEPRESSION: A SYSTEMATIC REVIEW AND META-ANALYSIS

MODEL-PREDICTED LYMPHOCYTE RESPONSE AND RECOVERY PROFILES FOR THE SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATORS OZANIMOD AND ETRASIMOD
MODEL-PREDICTED LYMPHOCYTE RESPONSE AND RECOVERY PROFILES FOR THE SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATORS OZANIMOD AND ETRASIMOD

A PHASE 1 DRUG INTERACTION STUDY EVALUATING THE EFFECTS OF ITRACONAZOLE ON THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF ETRASIMOD IN HEALTHY VOLUNTEERS
A PHASE 1 DRUG INTERACTION STUDY EVALUATING THE EFFECTS OF ITRACONAZOLE ON THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF ETRASIMOD IN HEALTHY VOLUNTEERS

PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF ETRASIMOD: RESULTS FROM A PHASE 1 DRUG-DRUG INTERACTION STUDY IN HEALTHY VOLUNTEERS
PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF ETRASIMOD: RESULTS FROM A PHASE 1 DRUG-DRUG INTERACTION STUDY IN HEALTHY VOLUNTEERS

SURGICAL RESECTIONS FROM IBD PATIENTS EXHIBIT DIFFERENT METABOLITE-SENSING GPCRS EXPRESSION, METABOLIC PROFILES AND MICROBIAL DYSBIOSIS
SURGICAL RESECTIONS FROM IBD PATIENTS EXHIBIT DIFFERENT METABOLITE-SENSING GPCRS EXPRESSION, METABOLIC PROFILES AND MICROBIAL DYSBIOSIS

SWITCHING INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB WAS SAFE AND SUCCESSFUL SHORT TERM IN ULCERATIVE COLITIS AND CROHN PATIENTS – A BELGIAN SINGLE CENTER EXPERIENCE
SWITCHING INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB WAS SAFE AND SUCCESSFUL SHORT TERM IN ULCERATIVE COLITIS AND CROHN PATIENTS – A BELGIAN SINGLE CENTER EXPERIENCE

PROTEOMIC PROFILE OF SERUM AND URINE IN NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE: NEW APPROACH FOR BIOMARKER DISCOVERY
PROTEOMIC PROFILE OF SERUM AND URINE IN NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE: NEW APPROACH FOR BIOMARKER DISCOVERY

USTEKINUMAB THERAPY AFTER BIOLOGIC FAILURE IN PATIENTS WITH CROHN’S DISEASE – A REAL-WORLD SINGLE CENTRE EXPERIENCE
USTEKINUMAB THERAPY AFTER BIOLOGIC FAILURE IN PATIENTS WITH CROHN’S DISEASE – A REAL-WORLD SINGLE CENTRE EXPERIENCE

SEROLOGIC RESPONSE WITH ANTIMICROBIAL ANTIBODIES DURING THE PRECLINICAL PHASE OF INFLAMMATORY BOWEL DISEASE
SEROLOGIC RESPONSE WITH ANTIMICROBIAL ANTIBODIES DURING THE PRECLINICAL PHASE OF INFLAMMATORY BOWEL DISEASE

ECONOMIC IMPACT OF INFLAMATORY BOWEL DISEASE IN CATALONIA.A POPULATION-BASED ANALYSIS
ECONOMIC IMPACT OF INFLAMATORY BOWEL DISEASE IN CATALONIA.A POPULATION-BASED ANALYSIS

EFFICACY AND SAFETY OF MIRIKIZUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-1 STUDY
EFFICACY AND SAFETY OF MIRIKIZUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-1 STUDY

RISK FACTORS AND LONG-TERM OUTCOMES ASSOCIATED WITH IMMUNOSUPPRESSION IN PATIENTS WITH ULCERATIVE PROCTITIS: RESULTS FROM THE ENEIDA REGISTRY
RISK FACTORS AND LONG-TERM OUTCOMES ASSOCIATED WITH IMMUNOSUPPRESSION IN PATIENTS WITH ULCERATIVE PROCTITIS: RESULTS FROM THE ENEIDA REGISTRY

COVID19 VACCINATION COVERAGE IN FLEMISH PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES
COVID19 VACCINATION COVERAGE IN FLEMISH PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES

MORE SEVERE CROHN’S DISEASE CLINICAL PRESENTATION IN AN INFLAMMATORY BOWEL DISEASE (IBD) CENTER OF EMERGENCY DEPARTMENT DURING COVID-19 PANDEMIC
MORE SEVERE CROHN’S DISEASE CLINICAL PRESENTATION IN AN INFLAMMATORY BOWEL DISEASE (IBD) CENTER OF EMERGENCY DEPARTMENT DURING COVID-19 PANDEMIC

ASSOCIATION OF ANTIBIOTIC USE WITH DURABILITY OF BIOLOGIC AGENTS IN INFLAMMATORY BOWEL DISEASE: A REPORT FROM THE EPI-IIRN
ASSOCIATION OF ANTIBIOTIC USE WITH DURABILITY OF BIOLOGIC AGENTS IN INFLAMMATORY BOWEL DISEASE: A REPORT FROM THE EPI-IIRN

THE RISK OF SERIOUS INFECTIONS BEFORE AND AFTER ANTI-TNF THERAPY IN INFLAMMATORY BOWEL DISEASE – A RETROSPECTIVE COHORT STUDY
THE RISK OF SERIOUS INFECTIONS BEFORE AND AFTER ANTI-TNF THERAPY IN INFLAMMATORY BOWEL DISEASE – A RETROSPECTIVE COHORT STUDY

EFFICACY, PERSISTENCE AND OPTIMIZATION OF USTEKINUMAB IN ULCERATIVE COLITIS: CLINICAL DATA
EFFICACY, PERSISTENCE AND OPTIMIZATION OF USTEKINUMAB IN ULCERATIVE COLITIS: CLINICAL DATA

REDUCED HUMORAL RESPONSE TO TWO DOSES OF COVID-19 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA FROM ESCAPE-IBD, AN IG-IBD STUDY
REDUCED HUMORAL RESPONSE TO TWO DOSES OF COVID-19 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA FROM ESCAPE-IBD, AN IG-IBD STUDY

PREDICTOR OF THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH SEVERE ULCERATIVE COLITIS AND MEASURES FOR THEIR PREVENTION
PREDICTOR OF THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH SEVERE ULCERATIVE COLITIS AND MEASURES FOR THEIR PREVENTION

Item 281 - 300 / 612
1 2 3 4 5 6 7 8 9 10 11 12 13 14
15
16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31